Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges
Cell therapy has proven to be a burgeoning field of investigation, evidenced by hundreds of clinical trials being conducted worldwide across a variety of cell types and indications. Many cell therapies have been shown to be efficacious in humans, such as modified T-cells and natural killer (NK) cell...
Main Authors: | Rohin K. Iyer, Paul A. Bowles, Howard Kim, Aaron Dulgar-Tulloch |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-05-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2018.00150/full |
Similar Items
-
Commercial Scale Manufacturing of Allogeneic Cell Therapy
by: Gary M. Pigeau, et al.
Published: (2018-08-01) -
Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions
by: Peng Zhang, et al.
Published: (2022-07-01) -
Adoptive Immunotherapy beyond CAR T-Cells
by: Aleksei Titov, et al.
Published: (2021-02-01) -
T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
by: Elien De Bousser, et al.
Published: (2021-12-01) -
Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression
by: Wei Jiang, et al.
Published: (2023-11-01)